AstraZeneca enjoys rise in profits

Anglo-Swedish drugs giant AstraZeneca today reported an 8% rise in profits for the last quarter, helped by sales of its new ulcer treatment Nexium and asthma drug Symbicort, the group said today.

AstraZeneca enjoys rise in profits

Anglo-Swedish drugs giant AstraZeneca today reported an 8% rise in profits for the last quarter, helped by sales of its new ulcer treatment Nexium and asthma drug Symbicort, the group said today.

Pre-tax profits for the three months to June 30 rose to €1.1bn, while sales improved 8% to €4.4bn.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited